Improved assessments of risk have now been defined based on mutations in BRCA1 (Breast Cancer susceptibility gene 1: 39%–65% life-time risk), and BRCA2 (Breast Cancer susceptibility gene 2: 11%–37% life-time risk) [40,41]. This evidence concerns the gene BRCA2 and breast carcinoma.